• 1
    Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. J Am Coll Cardiol 2004; 44: 72032.
  • 2
    Phatak H, Wentworth C, Sazonov Kocevar V, Burke TA. Prevalence and predictors of lipid abnormalities in patients treated with statins in the UK general. Atheresclerosis 2009; 202: 22533.
  • 3
    Rajagopalan S, Alemao E, Finch L, Yin D. Impact of new Joint British Societies’ (JBS 2) guidelines on prevention of cardiovascular disease: evaluation of serum total cholesterol goal achievement in UK clinical practice. Curr Med Res Opin 2007; 23: 202734.
  • 4
    Van Ganse E, Laforest L, Burke T, Phatak H, Souchet T. Mixed dyslipidemia among patients using lipid lowering therapy in French general practice: an observational study. Clin Ther 2007; 29: 167181.
  • 5
    National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143421.
  • 6
    Guyton JR, Goldber AC, Kreisberg RA, Sprecher DL, Superko R, O’Connor CM. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol 1998; 82: 73743.
  • 7
    Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary artery disease. Meta-analysis of prospective studies. Circulation 2000; 102: 10825.
  • 8
    Kamal-Bahl S, Burke T, Watson D, Wentworth C. Discontinuation of Lipid Modifying Drugs Among Commercially Insured United States Patients in Recent Clinical Practice. Am J Cardiol 2007; 99: 5304.
  • 9
    Alsheikh-Ali AA, Lin JL, Abourjaily P, Ahearn D, Kuvin JT, Karas RH. Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol. Am J Cardiol 2007; 100: 1499501.
  • 10
    Sarawate CA, Cziraky MJ, Stanek EJ, Willey VJ, Corbelli JC, Charland SL. Achievement of Optimal Combined Lipid Values in a Managed Care Setting: is a New Treatment Paradigm Needed? Clin Ther 2007; 29: 196209.
  • 11
    Dorais M, Chirovsky D, Ambegaonkar BM et al. Utilization patterns of extended-release niacin in Canada: analysis of an administrative claims database. Can J Cardiol; in press.
  • 12
    Marentette M, Cadieux P, Chan P, Sazonov V. Mixed dyslipidemia among Canadian patients using lipid-lowering therapy. Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke Conference, 9–11 May 2007, vol. 200, p. 15(P68).
  • 13
    Böhler S, Scharnagl H, Freisinger F et al. Unmet needs in the diagnosis and treatment of dyslipidemia in the primary care setting in Germany. Atherosclerosis 2007; 190: 397407.
  • 14
    Knopp RH, Ginsberg J, Albers JJ et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism 1985; 34: 64250.
  • 15
    Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Increasing HDL cholesterol with extended-release nicotinic acid: from promise to practice. Neth J Med 2004; 62: 22934.
  • 16
    Illingworth DR, Stein EA, Mitchel YB et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia: a prospective trial. Arch Intern Med 1994; 154: 158695.
  • 17
    Mills E, Prousky J, Raskin G et al. The safety of over-the-counter niacin. A randomized placebo-controlled trial. BMC Clin Pharmacol 2003; 3: 411.
  • 18
    Cheng K, Wu TJ, Wu KK et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci USA 2006; 103: 66827.
  • 19
    Sturino CF, O’Neill G, Lachance N et al. Discovery of a Potent and Selective Prostaglandin D(2) Receptor Antagonist, [(3R)-4-(4-Chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic Acid (MK-0524). J Med Chem 2007; 50: 794806.
  • 20
    Paolini JF, Mitchel YB, Reyes R et al. Effects of laropiprant on nicotinic acid-induced flushing in dyslipidemic patients. Am J Cardiol 2008; 101: 62530.
  • 21
    Maccubbin D, Bays HE, Olsson AG et al. Lipid-modifying efficacy and tolerability of extended release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract 2008; 62: 195970.
  • 22
    The coronary drug project. JAMA 1972; 221: 918.
  • 23
    Brown BG, Zhao XQ, Chait A et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345: 158392.
  • 24
    Brown BG, Hillger L, Zhao XQ, Poulin D, Albers JJ. Types of change in coronary stenosis severity and their relative importance in overall progression and regression in coronary disease. Observations from the FATS trial. Familial Atherosclerosis Treatment study. Ann NY Acad Sci 1995; 748: 40717.
  • 25
    The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231: 36081.
  • 26
    Canner PL, Berge KG, Wenger NK et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8: 124555.
  • 27
    Maccubbin D, Koren MJ, Davidson M et al. Flushing profile of extended release niacin/laropiprant versus gradually titrated niacin extended release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol 2009; 104: 7481.
  • 28
    Ariyo AA, Thach C, Tracy R, the Cardiovascular Health Study Investigators. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. N Engl J Med 2003; 349: 210815.
  • 29
    Guyton JR, Bays HE. Safety considerations with niacin therapy. Am J Cardiol 2007; 99 (Suppl.): 22C31C.
  • 30
    Tatò F, Vega GL, Grundy SM. Effects of crystalline nicotinic acid-induced hepatic dysfunction of serum low-density lipoprotein cholesterol and lecithin cholesteryl acyl transferase. Am J Cardiol 1998; 81: 8057.
  • 31
    Rader JI, Calvert RJ, Hathcock JN. Hepatic toxicity of unmodified and time-release preparations of niacin. Am J Med 1992; 92: 7781.
  • 32
    Grundy SM, Vega GL, McGovern ME et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dysplipidemia associated with type 2 diabetes – results of the assessment of diabetes control and evaluation of the efficacy of Niaspan trial. Arch Intern Med 2002; 162: 156876.
  • 33
    Elam MB, Hunninghake DB, Davis KB et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. JAMA 2000; 284: 126370.